

# Interferon beta tied to spike in thrombotic microangiopathy

27 March 2014



Image courtesy of Blausen Medical

share the same formulation as that used in the United Kingdom.

"We did not detect such patterns or trends in the safety data from a similar recombinant [interferon beta](#) product, suggesting that further investigation of the association with changes in manufacturing may be worthwhile," the authors write.

**More information:** [Full Text](#)

Copyright © 2014 [HealthDay](#). All rights reserved.

(HealthDay)—There has been an unusually high number of cases of thrombotic microangiopathy associated with severe or malignant hypertension in patients with multiple sclerosis who were receiving therapy with recombinant interferon beta, according to a letter to the editor published in the March 27 issue of the *New England Journal of Medicine*.

David Hunt, Ph.D., from Edinburgh University in the United Kingdom, and colleagues reviewed case histories and pharmacy records to describe an unexpectedly high number of cases of thrombotic microangiopathy associated with severe or malignant hypertension in four patients with [multiple sclerosis](#) who were receiving therapy with recombinant interferon beta in South Scotland. All patients presented after years of well-tolerated treatment with interferon beta.

The researchers found no genetic or other causal factor for thrombotic microangiopathy, but did note a significant association with a common manufacturing source of interferon beta (Rebif, Merck). Geographical and temporal distribution of the hemolytic-uremic syndrome and thrombotic thrombocytopenic purpura reports shows that very few cases were reported globally in the first nine years of safety monitoring, but that there has been a recent increase in reports from countries that

APA citation: Interferon beta tied to spike in thrombotic microangiopathy (2014, March 27) retrieved 24 January 2022 from <https://medicalxpress.com/news/2014-03-interferon-beta-tied-spike-thrombotic.html>

*This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.*